| Name | Title | Contact Details |
|---|
Pella Regional Health Center is a critical access hospital in central Iowa with integrated family practice, internal medicine providers as well as general surgeons and gynecologists. Pella Regional has medical clinics in five communities (Pella, Knoxville, Monroe, Sully and Bussey) and outpatient services like Hospice of Pella and Home Health Care that extend well beyond the walls of the hospital. In addition a new clinic was added in Ottumwa in Fall 2012, and an occupational health clinic opened in Newton in Spring 2012.
Human Care HC Sweden AB is a Austin, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Xperiome is a global healthtech company that helps pharma get to know rare disease patients and their conditions faster by delivering deep insights into the patient experience. We have created Raremark as the place for the lived experience of rare disease. Raremark supports every stage of a patient`s health odyssey: a community to crowdsource wisdom, a library to catalog the lived experience, and a matching engine to find research opportunities. This data-driven knowledge bank of the rare experience allows us to match research-ready members to clinical and real-world studies, faster and smarter than ever before.
Familymeds Group Inc is a Farmington, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Delphinus Medical Technologies, Inc. is an innovation leader in advanced ultrasound development, introducing a dynamic new technique to image the breast with the use of sound and water. Delphinus is committed to creating improved imaging methods that assist medical professionals to better define and diagnose breast disease, while establishing a better patient experience that can be available for all women, regardless of age, without the concern of radiation or pain. Headquartered in Plymouth, MI, Delphinus is the first company to design and manufacture a whole breast ultrasound system that utilizes a ring transducer to transmit and receive ultrasound signals. Known as SoftVue™, three critical sound characteristics are measured and refined through proprietary algorithms, advancing this technology far beyond traditional b-mode ultrasound. By collecting and defining reflection, sound speed, and attenuation data in a 360° orientation, data are gathered and reconstructed in tomographic coronal planes, providing an enriched image set presented for cross-sectional review. SoftVue has received FDA clearance for diagnostic imaging purposes and is not intended for use as a replacement for screening mammography. Delphinus was formed in 2010 as a spin-out of Karmanos Cancer Institute [KCI] in Detroit, MI. Created by Peter Littrup, MD of Karmanos and Neb Duric, PhD of Wayne State University Detroit, MI the SoftVue technology presents a new imaging paradigm in breast disease assessment. Karmanos Cancer Institute has served as a primary investigational site for case collection and clinical studies. Delphinus holds numerous patents and proprietary assets for its innovative and scientifically-advanced works and is poised to usher in a new era of breast imaging.